Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol + trimegestone is a fixed-dose combination of two hormones used primarily in menopausal hormone therapy. Estradiol is a natural estrogen that acts as an agonist at estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), alleviating vasomotor symptoms and preventing postmenopausal osteoporosis by regulating gene transcription in target tissues[3][4][5]. Trimegestone is a potent synthetic progestin (19-norpregnane derivative) with high affinity for the progesterone receptor and minimal activity at androgenic, glucocorticoid, or mineralocorticoid receptors[1][2]. In this combination, estradiol provides estrogenic effects while trimegestone counteracts the risk of endometrial hyperplasia associated with unopposed estrogen therapy. The product is indicated for the treatment of climacteric (menopausal) symptoms and prevention of post-menopausal bone loss[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + trimegestone.